Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.
about
Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugsThe Trafficking of the Water Channel Aquaporin-2 in Renal Principal Cells-a Potential Target for Pharmacological Intervention in Cardiovascular DiseasesPharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptorsPharmacological chaperoning: a primer on mechanism and pharmacologyEmerging novel concept of chaperone therapies for protein misfolding diseasesA novel therapeutic effect of statins on nephrogenic diabetes insipidusProtein trafficking defects in inherited kidney diseasesHow genetic errors in GPCRs affect their function: Possible therapeutic strategiesA phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptorTrafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.Using pharmacological chaperones to restore proteostasisFunctional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.Chaperoning G protein-coupled receptors: from cell biology to therapeuticsA small molecule agonist THIQ as a novel pharmacoperone for intracellularly retained melanocortin-4 receptor mutants.Rare inherited kidney diseases: challenges, opportunities, and perspectives.Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy.High-throughput screen for pharmacoperones of the vasopressin type 2 receptorNovel mutation in the AVPR2 gene in a Danish male with nephrogenic diabetes insipidus caused by ER retention and subsequent lysosomal degradation of the mutant receptor.Escorts take the lead molecular chaperones as therapeutic targetsPharmacological chaperones for misfolded gonadotropin-releasing hormone receptorsAssay strategies for identification of therapeutic leads that target protein traffickingPharmacological chaperone therapy for Fabry diseaseA Rare Case of Congenital Diabetes Insipidus.Vasopressin receptor antagonists and their role in clinical medicine.Partial nephrogenic diabetes insipidus caused by a novel AQP2 variation impairing trafficking of the aquaporin-2 water channel.The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes InsipidusSignaling Modification by GPCR Heteromer and Its Implication on X-Linked Nephrogenic Diabetes Insipidus.Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro.Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment.Conivaptan: a step forward in the treatment of hyponatremia?Agonist-independent interactions between beta-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis.Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.Enhancement of the surface expression of G protein-coupled receptors.Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.Chaperone-like effects of cell-permeant ligands on opioid receptors.Pediatric disorders of water balance.Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.Genetic testing in renal disease.
P2860
Q21089948-238F6B59-82EB-4317-B804-50E41EC20B8BQ26768170-021FAC98-4819-41F3-B2A5-FC8581CFDF2AQ26992276-909BE81B-3115-44DD-8CA0-3284C81DAF23Q27001695-65A89D84-EE8A-4198-8CA6-00926AA4888DQ27002907-7CFB33F5-7351-454E-B33F-C7CE8BD85233Q27005638-0ECF1A90-6EC5-47CE-A2B6-17A1216045F8Q27012909-BC7989D1-A273-4D44-99A0-AEA9CA08FFD1Q28646207-D306C580-02D8-4E25-A21A-2DBAE58A2635Q33629937-566FC59C-2EB8-486C-888B-147BED6D9557Q33699210-F5BAB694-DFF6-42E6-BEB4-7095036F569FQ33717398-06BA5091-3C7C-4278-A410-60817A71CD9DQ33804655-9AC7CED5-0C42-494C-94FE-3E8A742D759AQ33862041-859A2FD7-90A8-460B-ACB7-504B3595F453Q33927508-2FCD622C-FC42-475A-A7CD-41376CDD9990Q33970155-C2A22AAC-7AC7-4229-9AC0-0D4EC84368C8Q34054113-D1633013-DCA8-4CBD-8438-39F0B1557DF2Q34390847-3DC4649C-18F8-4EA7-8F9B-013DD9511224Q34703957-66657F1A-E487-4813-BF7E-7DAEB8C11955Q35012380-B5CBE7AB-E527-4C16-8B0A-21C4A95CAE46Q35075365-033E92C4-B64C-4C41-82C5-92BEE3789DB7Q35606973-0C131752-AEBF-4C17-8B31-4CFDBB0CE286Q35661403-CFB1C5A5-22BC-4233-9B7D-A76092E16961Q35755438-05A6D609-C2AD-45E4-910A-3C8ED5787A24Q35824173-33C05618-E313-4E7E-B591-4E7ED0BA8C58Q35856033-82A558F7-5744-4CAD-B7F8-D94E67805E72Q35881045-9A82546F-C7D5-4959-A719-38340CD9F550Q36003378-37C27F65-5F47-4902-942D-90503AAE9042Q36046576-B65E185C-A741-4738-A1D6-9B5E30C74022Q36138589-56CEF5F6-1E51-480E-95C7-3AB8F0D34CC5Q36316416-F83D91C3-731E-4C3E-9580-72308D04AF2BQ36724058-DE9ACA76-8878-403F-B449-874A52FB8482Q36823541-60D32897-AD0A-45BD-9738-C2F375C4CB91Q37155408-CE76552D-8916-47F6-B9AC-C20C44F6B9E7Q37274407-9A09CE73-7287-4D3D-B3CC-AAA41EE547A6Q37316198-7844D7E7-9807-419E-9EA6-73A315313EFFQ37351126-527B2216-6A38-45E4-B25F-9BEA2624E65CQ37410011-8E3AFE30-FC8D-4DBC-BAD0-976C80E1E77AQ37640345-F3810552-75A5-4DAD-95FA-656BDED63BD4Q37668227-2D1F58FE-A5E8-4820-9886-95B1C66DC07EQ37880653-4270DFD2-C785-4E1A-A694-438E7540CAB4
P2860
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.
@en
Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.
@nl
type
label
Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.
@en
Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.
@nl
prefLabel
Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.
@en
Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.
@nl
P2093
P356
P1476
Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.
@en
P2093
Alexandro Zarruk
Ali Salahpour
André Laperrière
Daniel G Bichet
Jean-Pierre Morello
Marie-Françoise Arthus
Michèle Lonergan
Nicolas Debrand
Rémi Brouard
Virginie Bernier
P304
P356
10.1681/ASN.2005080854
P577
2005-11-30T00:00:00Z